← Back to feed

Ixico

IXI · AIM · Health Care · mcap £17m today

All announcements

All RNS · 41 Key events · 29

01 Oct 26

IXICO present PD research at radiology conference

IXICO to present advancements in neuroimaging for Parkinson’s disease at European radiology conference
RNS 9800296 ↗
27 Jul 26

Share option award

27 July 2026: IXICO plc (AIM: IXI), IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development and diagnostics in neurological disorders, today announced that the Company has issued...
RNS 9689469 ↗
15 Jul 26

Director/PDMR Shareholding Director buys

15 July 2026: IXICO plc (AIM: IXI), IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development and diagnostics in neurological disorders, announces that it has been notified that on...
RNS 9670504 ↗
13 Jul 26

HD Industry Update

13 July 2026: IXICO plc (AIM: IXI), IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development and diagnostics in neurological disorders, notes the continued evolution of the...
RNS 9664195 ↗
07 Jul 26

Trading Update

Revenue anticipated to be ahead of expectations for the year ending 30 September 2026
RNS 9654825 ↗
19 Jun 26

Exercise of Options
RNS 9626567 ↗
08 Jun 26

Scientific advisors & partners update

IXICO EXPANDS RESEARCH COLLABORATIONS IN ALZHEIMER'S AND PARKINSON'S DISEASE
RNS 9605268 ↗
22 May 26

Company presentation at Mello 2026

22 May 2026, IXICO plc (AIM: IXI) - London, UK.
RNS 9581363 ↗
21 May 26

Contract win and contract extension

Alzheimer's contract win and Phase 2 clinical trial contract extension with total value of £1.3 million
RNS 9578728 ↗
19 May 26

Half-year Results

Interim results for six months ending 31 March 2026
RNS 9574199 ↗
12 May 26

IXICO Updates AI Neuroimaging Platform

IXICO RELEASES LATEST VERSION OF AI-DRIVEN NEUROIMAGING TECHNOLOGY PLATFORM
RNS 9562828 ↗
28 Apr 26

Holding(s) in Company
RNS 9542370 ↗
28 Apr 26

Holding(s) in Company
RNS 9542316 ↗
28 Apr 26

Holding(s) in Company
RNS 9542131 ↗
28 Apr 26

Holding(s) in Company
RNS 9541971 ↗
27 Apr 26

Holding(s) in Company
RNS 9540176 ↗
27 Apr 26

Holding(s) in Company
RNS 9540162 ↗
27 Apr 26

Holding(s) in Company
RNS 9540156 ↗
27 Apr 26

Holding(s) in Company
RNS 9539971 ↗
27 Apr 26

Holding(s) in Company
RNS 9539635 ↗
24 Apr 26

Holding(s) in Company
RNS 9537832 ↗
22 Apr 26

Issue of Equity
RNS 9533135 ↗
21 Apr 26

Trading Update

Half-year Trading update and Notice of Interim Results
RNS 9529275 ↗
16 Apr 26

Result of GM and Update on Issue of Equity

Result of General Meeting and Update on Issue of Equity
RNS 9524119 ↗
07 Apr 26

Result of Retail Offer

IXICO is pleased to announce that the Retail Offer launched on 31 March 2026 has now closed, raising gross proceeds of £30,320.
RNS 9508690 ↗
31 Mar 26

Retail Offer

IXICO is pleased to announce a retail offer via the BookBuild Platform (the "Retail Offer") of up to 6,250,000 new ordinary shares ("Ordinary Shares") of £0.01 each in the capital of the Company (the "Retail Offer Shares") at an issue price of 8 pence per...
RNS 9499392 ↗
31 Mar 26

Placings and Subscription

THIS ANNOUNCEMENT SHOULD BE READ IN ITS ENTIRETY.
RNS 9499214 ↗
26 Mar 26

Collaboration with Medidata

IXICO and Medidata collaborate to create an advanced neuroimaging clinical trials platform
RNS 9492601 ↗
26 Feb 26

Validation of Neuroimaging Technology Platform

26 February 2026, IXICO plc (AIM: IXI) - London, UK.
RNS 9447702 ↗
12 Feb 26

C.£1.5 million Contract Extension

The following amendment has been made to the "c.£1.5 million Contract Extension" announcement released at 07:00 on 12 February 2026:
RNS 9427870 ↗
12 Feb 26

C.£1.5 million Contract Extension

c.£1.5 million contract extension on global Phase 2 clinical trial
RNS 9427006 ↗
05 Feb 26

Appointment of Chief Commercial Officer

IXICO appoints Chief Commercial Officer to accelerate business development activity and broaden US footprint
RNS 9410111 ↗
23 Jan 26

Result of AGM

IXICO plc (AIM: IXI), a global leader in neuroscience precision medicine and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, announces that all resolutions put forward to its Annual General...
RNS 9381002 ↗
09 Dec 25

Share option award

9 December 2025 IXICO plc (AIM: IXI) - London, UK.
RNS 9284008 ↗
09 Dec 25

Financial Results for year ended 30 September 2025

Financial Results for year ended 30 September 2025 and Notice of AGM
RNS 9283736 ↗
01 Dec 25

Operational Update

IXICO strengthens Scientific Advisory Board with two prominent global Alzheimer's Disease and vascular experts
RNS 9265833 ↗
27 Nov 25

Notice of 2025 Full Year Results and IMC

Notice of 2025 Full Year Results and Investor Presentation
RNS 9260022 ↗
17 Nov 25

Clinical Trial Contract Win

Global Phase 3 clinical trial contract win worth over £3.5 million
RNS 9236517 ↗
03 Nov 25

Capital Markets Day Presentation and Video

03 November 2025 IXICO plc (AIM: IXI) - London, UK.
RNS 9209527 ↗
16 Oct 25

Trading Update

Trading update for the year ended 30 September 2025
RNS 9173985 ↗
15 Oct 25

New contract win and contract extension

contract extension worth a total of £1.2 million.
RNS 9171237 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.